Armine Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Armine Smith has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Andres Matoso
Johns Hopkins School of Medicine
2 shared publications - Ezra Baraban
Johns Hopkins School of Medicine, Baltimore, MD
2 shared publications Max Kates
James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD
2 shared publicationsSunil Patel
James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD
2 shared publicationsAlyssa Arbuiso
Johns Hopkins School of Medicine, Baltimore, MD
1 shared publication- Amanda Smart
Department of Urology, George Washington University Hospital, Washington, DC, USA
1 shared publication
Latest Publications
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (10)
Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab
PURPOSE: Enfortumab vedotin and pembrolizumab (EVP) is the standard first-line treatment for locally advanced and metastatic urothelial cancer (la/mUC) although response biomarkers remain an unmet need. Tumor-informed circulating tumor DNA (ctDNA) has proven to be useful as a marker of response in a variety of cancers. We sought to explore whether ctDNA dynamics is associated with survival outcomes. METHODS: This retrospective study included patients with la/mUC receiving first-line EVP, who had plasma ctDNA collected using the Signatera assay within 3 months after treatment initiation. Associations between ctDNA clearance and overall survival (OS) and progression-free survival (PFS) were assessed using multivariable time-dependent Cox proportional hazard (CPH) models and landmark analyses at 1, 2, and 3 months after EVP initiation. Longitudinal ctDNA trends were examined in a subpopulation with baseline ctDNA values collected. RESULTS: Fifty-eight patients were included. In multivariable time-dependent CPH models, ctDNA clearance was associated with both OS (hazard ratio [HR], 0.04 [95% CI, 0.01 to 0.24], P < .001) and PFS (HR, 0.09 [95% CI, 0.02 to 0.32], P < .001). In landmark analyses, ctDNA clearance was associated with longer OS and PFS at 2 months (log-rank test P = .003, P < .001, respectively). Among patients with baseline ctDNA (n = 42), 69% achieved ctDNA clearance after EVP initiation, whereas just 14% (n = 6) never had a decrease in ctDNA. The median time to clearance of ctDNA was 1.41 months (IQR, 0.85-1.94). CONCLUSION: While primarily hypothesis-generating, this study suggests that patients with la/mUC treated with first-line EVP frequently and rapidly clear ctDNA. Clearance of ctDNA in this population is associated with longer survival and merits further study.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (10)
Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab
PURPOSE: Enfortumab vedotin and pembrolizumab (EVP) is the standard first-line treatment for locally advanced and metastatic urothelial cancer (la/mUC) although response biomarkers remain an unmet need. Tumor-informed circulating tumor DNA (ctDNA) has proven to be useful as a marker of response in a variety of cancers. We sought to explore whether ctDNA dynamics is associated with survival outcomes. METHODS: This retrospective study included patients with la/mUC receiving first-line EVP, who had plasma ctDNA collected using the Signatera assay within 3 months after treatment initiation. Associations between ctDNA clearance and overall survival (OS) and progression-free survival (PFS) were assessed using multivariable time-dependent Cox proportional hazard (CPH) models and landmark analyses at 1, 2, and 3 months after EVP initiation. Longitudinal ctDNA trends were examined in a subpopulation with baseline ctDNA values collected. RESULTS: Fifty-eight patients were included. In multivariable time-dependent CPH models, ctDNA clearance was associated with both OS (hazard ratio [HR], 0.04 [95% CI, 0.01 to 0.24], P < .001) and PFS (HR, 0.09 [95% CI, 0.02 to 0.32], P < .001). In landmark analyses, ctDNA clearance was associated with longer OS and PFS at 2 months (log-rank test P = .003, P < .001, respectively). Among patients with baseline ctDNA (n = 42), 69% achieved ctDNA clearance after EVP initiation, whereas just 14% (n = 6) never had a decrease in ctDNA. The median time to clearance of ctDNA was 1.41 months (IQR, 0.85-1.94). CONCLUSION: While primarily hypothesis-generating, this study suggests that patients with la/mUC treated with first-line EVP frequently and rapidly clear ctDNA. Clearance of ctDNA in this population is associated with longer survival and merits further study.
- Open Access
- 25 August 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (3)
Difficult conversations in bladder cancer survivorship: Integrating mental health and intimacy into routine urologic care
Introduction: Bladder cancer survivorship extends beyond oncologic control and includes significant psychological distress, demoralization, sexual dysfunction, and identity disruption. Despite their clinical relevance, structured approaches to difficult conversations in bladder cancer care remain inconsistent. Objective: To develop interdisciplinary consensus recommendations for integrating structured communication regarding mental health and intimacy into routine bladder cancer care. Methods: A multidisciplinary breakout session was convened during the 2025 Bladder Cancer Advocacy Network (BCAN) Think Tank. Participants included urologists, medical oncologists, psychiatrists, sexual medicine specialists, advanced practice providers, nurses, social workers, and patient advocates. The session combined didactic presentations with a moderated panel discussion structured around six predefined domains, followed by iterative refinement of consensus statements through follow up correspondence among the discussion leaders. Results: Consensus was achieved across six core domains: normalization of psychosocial discussions, routine screening, differentiation between depression and demoralization, structured sexual health counseling, early multidisciplinary referral pathways, and team-based survivorship implementation. A practical implementation framework was developed to integrate these domains into routine urologic practice. Conclusion: Difficult conversations are central to high-quality bladder cancer care. As practice-changing perioperative and metastatic therapies extend survival for a growing population of bladder cancer survivors, structured communication about mental health and intimacy becomes increasingly central to comprehensive care. The BCAN consensus provides structured, implementable recommendations to standardize communication around mental health and intimacy, with implications for survivorship outcomes and future research.
- 25 August 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (3)
Open AccessDifficult conversations in bladder cancer survivorship: Integrating mental health and intimacy into routine urologic care
Introduction: Bladder cancer survivorship extends beyond oncologic control and includes significant psychological distress, demoralization, sexual dysfunction, and identity disruption. Despite their clinical relevance, structured approaches to difficult conversations in bladder cancer care remain inconsistent. Objective: To develop interdisciplinary consensus recommendations for integrating structured communication regarding mental health and intimacy into routine bladder cancer care. Methods: A multidisciplinary breakout session was convened during the 2025 Bladder Cancer Advocacy Network (BCAN) Think Tank. Participants included urologists, medical oncologists, psychiatrists, sexual medicine specialists, advanced practice providers, nurses, social workers, and patient advocates. The session combined didactic presentations with a moderated panel discussion structured around six predefined domains, followed by iterative refinement of consensus statements through follow up correspondence among the discussion leaders. Results: Consensus was achieved across six core domains: normalization of psychosocial discussions, routine screening, differentiation between depression and demoralization, structured sexual health counseling, early multidisciplinary referral pathways, and team-based survivorship implementation. A practical implementation framework was developed to integrate these domains into routine urologic practice. Conclusion: Difficult conversations are central to high-quality bladder cancer care. As practice-changing perioperative and metastatic therapies extend survival for a growing population of bladder cancer survivors, structured communication about mental health and intimacy becomes increasingly central to comprehensive care. The BCAN consensus provides structured, implementable recommendations to standardize communication around mental health and intimacy, with implications for survivorship outcomes and future research.
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 14 (10) , 3268-3276
Sparing urethra in women at the time of cystectomy: retrospective comparison of cystectomies with and without urethrectomy
Background: In female patients undergoing cystectomy where orthotopic bladder reconstruction is not an option, urethrectomy is typically performed. Unlike in males, female urethrectomy carries a risk of damaging clitoral structures and nerves, potentially contributing to post-cystectomy sexual dysfunction. This study evaluates overall survival in women undergoing cystectomy with versus without urethrectomy. Methods: A retrospective review of electronic medical records from 2000 to 2023 was conducted. Radical cystectomy specimens were reviewed for surgical details, tumor characteristics, urethral involvement, and urethrectomy status. Institutional criteria required urethrectomy in patients receiving neobladder reconstruction. Results: Among 347 women who underwent cystectomy, 298 received urethrectomy and 49 did not. The mean age was 65.4 years. Urethral involvement was present in 15 cases (7%). One patient with a neobladder and positive urethral margin remained disease-free at 5 years. At the last follow-up, 54.2% of patients with urethrectomy and 61.2% without urethrectomy showed no evidence of disease. A total of 76 patients (26.5%) were alive with disease, 62 (20.8%) in the urethrectomy group and 14 (28.6%) in the non-urethrectomy group. Kaplan-Meier analysis showed mean overall survival of 246.9 months with urethrectomy vs. 173.9 months without. Propensity score matching (2:1) included 70 urethrectomy and 35 non-urethrectomy patients. Kaplan-Meier and Cox regression analyses showed no significant survival difference (P=0.07). Conclusions: Urethra-sparing cystectomy in women may be oncologically safe when no urethral involvement is present and should be considered to preserve sexual function.
- 1 October 2025
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 14 (10) , 3268-3276
Open AccessSparing urethra in women at the time of cystectomy: retrospective comparison of cystectomies with and without urethrectomy
Background: In female patients undergoing cystectomy where orthotopic bladder reconstruction is not an option, urethrectomy is typically performed. Unlike in males, female urethrectomy carries a risk of damaging clitoral structures and nerves, potentially contributing to post-cystectomy sexual dysfunction. This study evaluates overall survival in women undergoing cystectomy with versus without urethrectomy. Methods: A retrospective review of electronic medical records from 2000 to 2023 was conducted. Radical cystectomy specimens were reviewed for surgical details, tumor characteristics, urethral involvement, and urethrectomy status. Institutional criteria required urethrectomy in patients receiving neobladder reconstruction. Results: Among 347 women who underwent cystectomy, 298 received urethrectomy and 49 did not. The mean age was 65.4 years. Urethral involvement was present in 15 cases (7%). One patient with a neobladder and positive urethral margin remained disease-free at 5 years. At the last follow-up, 54.2% of patients with urethrectomy and 61.2% without urethrectomy showed no evidence of disease. A total of 76 patients (26.5%) were alive with disease, 62 (20.8%) in the urethrectomy group and 14 (28.6%) in the non-urethrectomy group. Kaplan-Meier analysis showed mean overall survival of 246.9 months with urethrectomy vs. 173.9 months without. Propensity score matching (2:1) included 70 urethrectomy and 35 non-urethrectomy patients. Kaplan-Meier and Cox regression analyses showed no significant survival difference (P=0.07). Conclusions: Urethra-sparing cystectomy in women may be oncologically safe when no urethral involvement is present and should be considered to preserve sexual function.
- 17 September 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (6) , 102224
Analysis of Neoadjuvant Chemotherapy Utilization, Pathologic Response, and Overall Survival in Upper Tract Urothelial Carcinoma
- 17 September 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (6) , 102224
Analysis of Neoadjuvant Chemotherapy Utilization, Pathologic Response, and Overall Survival in Upper Tract Urothelial Carcinoma
- Open Access
- 17 June 2022
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2022, 1-5
Metastasis to the Bladder: A Rare Site of Recurrence of Renal Cell Carcinoma
Renal cell carcinoma (RCC) is considered to be the deadliest urologic cancer with high rates of metastasis and recurrence after nephrectomy. RCC can metastasize to nearly any organ but most commonly metastasizes to the liver, lung, brain, and bone. To date, there are only about 40 reported cases of RCC with solitary bladder metastasis. The following report contributes to this limited data set of patients with RCC who develop solitary metastasis to the bladder. A 69-year-old male presented with occasional gross hematuria and was found to have a left renal mass infiltrating the collecting system. Ureteroscopic biopsy revealed clear cell RCC, and the patient subsequently underwent radical left nephrectomy. Eight months after nephrectomy, the patient presented to the clinic with gross hematuria. In-office cystoscopy demonstrated a nodular lesion in the bladder arising from the left ureteral orifice. The patient underwent transurethral resection of the bladder mass and pathology demonstrated clear cell RCC. Subsequent imaging showed no evidence of metastatic disease. Five months after transurethral resection, the patient was found to have a left distal ureteral mass and underwent left ureterectomy with partial cystectomy. Pathology again demonstrated clear cell RCC. RCC with solitary metastasis to the bladder is rare, and there are no targeted guideline recommendations for management. Per standard of care, patients with painless hematuria and risk factors for malignancy should undergo cystoscopy. In patients with a history of RCC, metastasis to the bladder should be considered in the differential diagnosis. Patients with metastatic RCC to the bladder should undergo a thorough work-up for additional sites of metastasis. In patients with RCC who develop solitary bladder metastasis amenable to resection following nephrectomy, there is a lack of evidence to guide therapy and a multidisciplinary discussion is warranted. However, if the tumor is amenable to resection, metastasectomy is a reasonable therapeutic approach and offers the patient an improved quality of life and an opportunity for remission.
- 17 June 2022
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2022, 1-5
Open AccessMetastasis to the Bladder: A Rare Site of Recurrence of Renal Cell Carcinoma
Renal cell carcinoma (RCC) is considered to be the deadliest urologic cancer with high rates of metastasis and recurrence after nephrectomy. RCC can metastasize to nearly any organ but most commonly metastasizes to the liver, lung, brain, and bone. To date, there are only about 40 reported cases of RCC with solitary bladder metastasis. The following report contributes to this limited data set of patients with RCC who develop solitary metastasis to the bladder. A 69-year-old male presented with occasional gross hematuria and was found to have a left renal mass infiltrating the collecting system. Ureteroscopic biopsy revealed clear cell RCC, and the patient subsequently underwent radical left nephrectomy. Eight months after nephrectomy, the patient presented to the clinic with gross hematuria. In-office cystoscopy demonstrated a nodular lesion in the bladder arising from the left ureteral orifice. The patient underwent transurethral resection of the bladder mass and pathology demonstrated clear cell RCC. Subsequent imaging showed no evidence of metastatic disease. Five months after transurethral resection, the patient was found to have a left distal ureteral mass and underwent left ureterectomy with partial cystectomy. Pathology again demonstrated clear cell RCC. RCC with solitary metastasis to the bladder is rare, and there are no targeted guideline recommendations for management. Per standard of care, patients with painless hematuria and risk factors for malignancy should undergo cystoscopy. In patients with a history of RCC, metastasis to the bladder should be considered in the differential diagnosis. Patients with metastatic RCC to the bladder should undergo a thorough work-up for additional sites of metastasis. In patients with RCC who develop solitary bladder metastasis amenable to resection following nephrectomy, there is a lack of evidence to guide therapy and a multidisciplinary discussion is warranted. However, if the tumor is amenable to resection, metastasectomy is a reasonable therapeutic approach and offers the patient an improved quality of life and an opportunity for remission.